---
layout: post
title: "Ethical Considerations for Clinical Investigations of Medical Products Involving Children; Draft Guidance for Industry, Sponsors, and Institutional Review Boards; Availability"
date: 2026-02-05 19:00:52 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-20720
original_published: 2022-09-26 00:00:00 +0000
significance: 8.00
---

# Ethical Considerations for Clinical Investigations of Medical Products Involving Children; Draft Guidance for Industry, Sponsors, and Institutional Review Boards; Availability

**Published:** February 05, 2026 19:00 UTC
**Source:** Federal Register
**Original Published:** September 26, 2022 00:00 UTC
**Document Number:** 2022-20720

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry, sponsors, and institutional review boards (IRBs) entitled "Ethical Considerations for Clinical Investigations of Medical Products Involving Children." This draft guidance describes FDA's current thinking regarding ethical considerations for clinical investigations of drugs, biological products, and medical devices (collectively referred to as "medical products" in this notice) involving children. The draft guidance is intended to assist industry, sponsors, and IRBs when considering the enrollment of children in clinical investigations of medical products.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/09/26/2022-20720/ethical-considerations-for-clinical-investigations-of-medical-products-involving-children-draft)
- API: https://www.federalregister.gov/api/v1/documents/2022-20720

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
